Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Chief Financial Officer | April 08, 2020 | April 09, 2020 |
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Financial Officer | September 01, 2026 | September 04, 2026 |
| IRIDEX CORPIRIX · Entity 7882 | CFO and VP Corp Development | November 24, 2018 | December 14, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date April 08, 2020 · Filed April 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 21,792 |
Reported balance
After 2020-04-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-08 · Grant · Acquired 21,792 · Balance 21,792 F1: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on April 8, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vest in full on April 8, 2021.
CORCEPT THERAPEUTICS INC
Report date September 01, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,268 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 138 · Balance 16,268 F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026. F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Common StockSEC Table I · non-derivative | Direct | 16,406 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 138 · Balance 16,406 F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Common StockSEC Table I · non-derivative | Direct | 16,304 |
Reported balance
After 2026-09-02 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-02 · Tax withholding · Disposed 102 · Balance 16,304 F5: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F6: The closing price on September 1, 2026 was used to calculate the withholding obligation. F7: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F2: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F5: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F6: The closing price on September 1, 2026 was used to calculate the withholding obligation.
F7: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
IRIDEX CORP
Report date November 24, 2018 · Filed December 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,787 |
Ending reported balance
After 2018-12-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-11-24 · Tax withholding · Disposed 5,833 · Balance 81,967 F1: Reflects shares withheld through November 24, 2018 in exempt dispositions to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent sales by the Reporting Person. Determination of the number of shares withheld was based upon the closing prices of the Issuer's Common Stock on the dates withheld. Row 2 · 2018-12-11 · Tax withholding · Disposed 180 · Balance 81,787 F2: These shares have been withheld in an exempt disposition to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares withheld through November 24, 2018 in exempt dispositions to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent sales by the Reporting Person. Determination of the number of shares withheld was based upon the closing prices of the Issuer's Common Stock on the dates withheld.
F2: These shares have been withheld in an exempt disposition to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2025 Filed Jun 5, 2025 00:32 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 775 | $71.68 | $55,552.00 |
DisclosureSEC source: 0000950170-25-081930 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,809 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025 F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 232 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 232 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032725 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,034 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 232 | $59.07 | $13,704.24 |
DisclosureSEC source: 0000950170-25-032725 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,802 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 228 | $60.58 | $13,812.24 |
DisclosureSEC source: 0000950170-25-032725 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,570 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on February 28, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 231 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032725 · ownership.xml · derivative · entry 4 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F7 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 231 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133432 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,798 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 231 | $59.21 | $13,677.51 |
DisclosureSEC source: 0000950170-24-133432 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,567 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 2, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 182 | $57.68 | $10,497.76 |
DisclosureSEC source: 0000950170-24-133432 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,336 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on November 29, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 400 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-104202 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,518 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 400 | $34.26 | $13,704.00 |
DisclosureSEC source: 0000950170-24-104202 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,118 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 6, 2024 00:24 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 143 | $35.30 | $5,047.90 |
DisclosureSEC source: 0000950170-24-104202 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,718 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on August 30, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,448 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,448 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069598 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,861 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,448 | $31.30 | $45,322.40 |
DisclosureSEC source: 0000950170-24-069598 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,413 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:10 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 571 | $30.17 | $17,227.07 |
DisclosureSEC source: 0000950170-24-069598 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,965 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on May 31, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 554 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 554 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026760 · ownership.xml · nonDerivative · entry 3 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,536 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F2 · balance_after: Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 554 | $24.06 | $13,329.24 |
DisclosureSEC source: 0000950170-24-026760 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,982 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F2 · balance_after: Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 02:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 517 | $24.06 | $12,439.02 |
DisclosureSEC source: 0000950170-24-026760 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,428 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: Includes 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 508 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014855 · ownership.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 508 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068364 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,945 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F4 · balance_after: Includes 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 23:53 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 508 | $25.97 | $13,192.76 |
DisclosureSEC source: 0000950170-23-068364 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,437 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: The Form 4 previously filed inadvertently overstated the number of shares held by 275. The number in Column 5 reflects the corrected amount. F4 · balance_after: Includes 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-046818 · ownership.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,204 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 398 | $33.10 | $13,173.80 |
DisclosureSEC source: 0000950170-23-046818 · ownership.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,806 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 1,651 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,651 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-014514 · doc4.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,408 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:03 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,651 | $22.97 | $37,923.47 |
DisclosureSEC source: 0000899243-23-014514 · doc4.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,757 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on June 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,260 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007054 · doc4.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,106 F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,260 | $19.86 | $25,023.60 |
DisclosureSEC source: 0000899243-23-007054 · doc4.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,846 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 793 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 13, 2023 Filed Feb 16, 2023 00:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.06 | $0.00 |
DisclosureSEC source: 0000899243-23-005174 · doc4.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-030514 · doc4.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586 F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 793 | $25.98 | $20,602.14 |
DisclosureSEC source: 0000899243-22-030514 · doc4.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 793 F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022. F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Read SEC document |
| February 02, 2022 Filed Feb 11, 2022 23:56 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000899243-22-005954 · doc4.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 2, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on February 2, 2026. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:58 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $25.46 | $0.00 |
DisclosureSEC source: 0000899243-21-009474 · doc4.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-02-28 F1 · derivative.exercise_date: Shares subject to the stock option vest and become exercisable with respect to 25% of the shares on the first anniversary of the date of grant with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on the fourth anniversary of the date of grant, subject to the Reporting Person's continued service. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 18:42 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 21,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-004836 · wf-form4_158645775951286.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,792 Underlying: Common Stock · 21,792 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on April 8, 2021. F2 · derivative.expiration_date: The RSUs vest in full on April 8, 2021. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 19:26 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 540,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001628280-20-000993 · wf-form4_158084435057170.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 540,000 shares Expires 2030-02-02 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 3, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 02:14 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-18-063787 · doc4.xml · derivative · entry 1 Mokari Atabak · CIK 0001678419 · Sr. VP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-12-18 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on December 19, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 14, 2018 01:57 UTC | IRIDEX CORP IRIX · Entity 7882 | Tax withholdingCommon Stock | 180 | $4.10 | $738.00 |
DisclosureSEC source: 0001704739-18-000057 · edgar.xml · nonDerivative · entry 2 Mokari Atabak · CIK 0001678419 · CFO and VP Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,787 F2 · shares: These shares have been withheld in an exempt disposition to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| November 24, 2018 Filed Dec 14, 2018 01:57 UTC | IRIDEX CORP IRIX · Entity 7882 | Tax withholdingCommon Stock | 5,833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001704739-18-000057 · edgar.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · CFO and VP Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,967 F1 · shares: Reflects shares withheld through November 24, 2018 in exempt dispositions to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent sales by the Reporting Person. Determination of the number of shares withheld was based upon the closing prices of the Issuer's Common Stock on the dates withheld. F1 · price: Reflects shares withheld through November 24, 2018 in exempt dispositions to the Issuer under Rule 16b-3(e), to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent sales by the Reporting Person. Determination of the number of shares withheld was based upon the closing prices of the Issuer's Common Stock on the dates withheld. Read SEC document |
| July 28, 2018 Filed Jul 31, 2018 20:17 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock | 16,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001704739-18-000039 · edgar.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · CFO and VP Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,800 F1 · shares: Represents the grant of restricted stock units ("RSUs"). The RSUs vest as to one-third of the shares on July 27, 2019 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 01:55 UTC | IRIDEX CORP IRIX · Entity 7882 | Exercise / conversionStock Option Right to Buy · Derivative | 63,000 | $0.00 Strike: $9.54 | $0.00 |
DisclosureSEC source: 0001704739-17-000015 · edgar.xml · derivative · entry 2 Mokari Atabak · CIK 0001678419 · CFO and VP Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,000 Underlying: Common Stock · 63,000 shares Expires 2024-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: This option was granted pursuant to IRIDEX Corporation's 2008 Equity Incentive Plan and is exempt to Rule 16b-3. F3 · derivative.exercise_date: Shares subject to the option vest over a period of 48 months with 1/4th of the total number of shares vesting on the first anniversary of the grant date and 1/48th of the total number of shares vesting each month thereafter. Read SEC document |
| July 24, 2017 Filed Jul 27, 2017 01:55 UTC | IRIDEX CORP IRIX · Entity 7882 | GrantCommon Stock | 6,000 | $9.54 | $57,240.00 |
DisclosureSEC source: 0001704739-17-000015 · edgar.xml · nonDerivative · entry 1 Mokari Atabak · CIK 0001678419 · CFO and VP Corp Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 F1 · balance_after: Restricted stock units vest over a period of 48 months with 1/4th of the total number of units vesting on the first anniversary of the grant date and 1/48th of the total number of units vesting each month thereafter. Restriced stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.